Cleo Diagnostics (ASX:COV) EPS (Basic) : A$-0.03 (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics EPS (Basic)?

Cleo Diagnostics's basic earnings per share (Basic EPS) for the six months ended in Dec. 2024 was A$-0.02. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.03.

Cleo Diagnostics's EPS (Diluted) for the six months ended in Dec. 2024 was A$-0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.03.

Cleo Diagnostics's EPS without NRI for the six months ended in Dec. 2024 was A$-0.02. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -0.03.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Cleo Diagnostics EPS (Basic) Historical Data

The historical data trend for Cleo Diagnostics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics EPS (Basic) Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Jun24

EPS (Basic)

-0.07

-0.03

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23	Jun24	Dec24
EPS (Basic)	-	-0.03	-0.02	-0.01	-0.02

Cleo Diagnostics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Cleo Diagnostics's Basic EPS for the fiscal year that ended in Jun. 2024 is calculated as

Basic EPS (A: Jun. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-3.759	-	0)	/	117.321
	=	-0.03

Cleo Diagnostics's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-1.95	-	0)	/	114.727
	=	-0.02

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.03

Cleo Diagnostics (ASX:COV) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cleo Diagnostics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics Headlines

No Headlines